Nuvalent (NASDAQ:NUVL) Insider Sells $309,065.96 in Stock

Nuvalent, Inc. (NASDAQ:NUVL) insider Christopher Durant Turner sold 3,181 shares of the stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $97.16, for a total transaction of $309,065.96. Following the completion of the sale, the insider owned 55,130 shares of the company’s stock, valued at approximately $5,356,430.80. The trade was a 5.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Christopher Durant Turner also recently made the following trade(s):

• On Monday, January 5th, Christopher Durant Turner sold 4,236 shares of Nuvalent stock. The stock was sold at an average price of $97.32, for a total value of $412,247.52.

Nuvalent Price Performance

Shares of NASDAQ:NUVL traded up $9.62 during midday trading on Wednesday, hitting $106.82. The company had a trading volume of 895,694 shares, compared to its average volume of 779,373. Nuvalent, Inc. has a twelve month low of $55.53 and a twelve month high of $112.88. The stock has a market cap of $7.77 billion, a price-to-earnings ratio of -20.08 and a beta of 1.32. The business’s 50-day simple moving average is $102.57 and its 200-day simple moving average is $88.78.

Nuvalent (NASDAQ:NUVL) last released its quarterly earnings data on Thursday, October 30th. The company reported ($1.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.39) by ($0.31). During the same period in the prior year, the business earned ($1.28) earnings per share. As a group, sell-side analysts forecast that Nuvalent, Inc. will post -3.86 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on NUVL shares. Robert W. Baird lifted their target price on shares of Nuvalent from $112.00 to $158.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 18th. Truist Financial set a $140.00 price target on shares of Nuvalent in a report on Monday, November 24th. Guggenheim upped their price objective on Nuvalent from $125.00 to $155.00 and gave the company a “buy” rating in a report on Tuesday, November 18th. Cantor Fitzgerald began coverage on Nuvalent in a research report on Wednesday, October 15th. They issued an “overweight” rating and a $135.00 price objective for the company. Finally, Canaccord Genuity Group began coverage on Nuvalent in a research report on Wednesday, November 12th. They issued a “buy” rating and a $126.00 target price on the stock. Fifteen equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $138.33.

Trending Headlines about Nuvalent

Here are the key news stories impacting Nuvalent this week:

• Negative Sentiment: CEO James Richard Porter sold 9,543 shares on Jan. 6 at an average $97.16 (≈ $927.2k); his post-sale holding was 278,629 shares (3.31% ownership drop). SEC Filing
• Negative Sentiment: CEO James Richard Porter sold 17,890 shares on Jan. 5 at an average $97.32 (≈ $1.74M); post-sale direct ownership 288,172 shares (5.85% ownership drop). SEC Filing
• Negative Sentiment: CFO Alexandra Balcom sold 3,181 shares on Jan. 6 at $97.16 (≈ $309.1k); post-sale holding 81,733 shares (3.75% ownership drop). SEC Filing
• Negative Sentiment: CFO Alexandra Balcom sold 4,236 shares on Jan. 5 at $97.32 (≈ $412.2k); post-sale holding 84,914 shares (4.75% ownership drop). SEC Filing
• Negative Sentiment: Insider Christopher Durant Turner sold 3,181 shares on Jan. 6 at $97.16 (≈ $309.1k); post-sale holding 55,130 shares (5.46% ownership drop). SEC Filing
• Negative Sentiment: Christopher Durant Turner sold 4,236 shares on Jan. 5 at $97.32 (≈ $412.2k); post-sale holding 58,311 shares (6.77% ownership drop). SEC Filing
• Negative Sentiment: Insider Deborah Ann Miller sold 2,589 shares on Jan. 6 at $97.16 (≈ $251.5k); post-sale holding 42,134 shares (5.79% ownership drop). SEC Filing
• Negative Sentiment: Deborah Ann Miller sold 4,363 shares on Jan. 5 at $97.32 (≈ $424.6k); post-sale holding 44,723 shares (8.89% ownership drop). SEC Filing
• Negative Sentiment: Insider Henry E. Pelish sold 2,664 shares on Jan. 6 at $97.17 (≈ $258.9k); post-sale holding 65,888 shares (3.89% ownership drop). SEC Filing
• Negative Sentiment: Henry E. Pelish sold 2,496 shares on Jan. 5 at $97.32 (≈ $242.9k); post-sale holding 68,552 shares (3.51% ownership drop). SEC Filing

Institutional Trading of Nuvalent

Several institutional investors have recently added to or reduced their stakes in the stock. RA Capital Management L.P. acquired a new position in Nuvalent during the third quarter worth $107,794,000. Wellington Management Group LLP grew its stake in shares of Nuvalent by 46.0% in the third quarter. Wellington Management Group LLP now owns 2,300,865 shares of the company’s stock valued at $198,979,000 after buying an additional 724,491 shares in the last quarter. Norges Bank purchased a new stake in shares of Nuvalent in the 2nd quarter valued at $28,582,000. Braidwell LP lifted its stake in Nuvalent by 39.8% during the 2nd quarter. Braidwell LP now owns 1,175,876 shares of the company’s stock worth $89,719,000 after acquiring an additional 334,931 shares in the last quarter. Finally, Polar Capital Holdings Plc boosted its holdings in Nuvalent by 25.3% during the 3rd quarter. Polar Capital Holdings Plc now owns 1,022,225 shares of the company’s stock valued at $88,402,000 after acquiring an additional 206,138 shares during the period. Institutional investors and hedge funds own 97.26% of the company’s stock.

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.